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Effects of glass and plastic containers on the physicochemical properties of propofol
injectable emulsion consisting of medium-chain triglycerides (MCTs) and long-chain tri-
glycerides (LCTs) after being diluted with 0.9% NaCl were evaluated. Propofol MCT/LCT
reconstituted with normal saline to 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL, 4.0 mg/mL, and 5.0
mg/mL were packaged into glass (type II soda-lime-silica), polyvinyl chloride (PVC) soft bag,
and non-PVC soft bag (Cryovac polyolefin soft bag container), and then stored at ambient
temperature/humidity (25  2 C/50  5% RH) for 3 days to test its stability. We found that
the pH and osmolarity of propofol injectable emulsions were consistent among different
formulations. All formulations packaged in glass and plastic containers were stable for 6
hours; the globule size distribution of these emulsions met the requirements described in
Chapter 729 of the United States Pharmacopeia. However, propofol formulations of higher
concentrations (3.0 mg/mL, 4.0 mg/mL, and 5.0 mg/mL) stored in plastic containers were
found to have abnormal globule size distribution profiles compared with those stored in
glass containers after 24 hours. We therefore recommend that the propofol MCT/LCT
emulsions should be packaged into glass containers and used within 6 hours after
reconstitution with diluents.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.Open access under CC BY-NC-ND license.1. Introduction (LCTs; 50:50 by weight). Two significant parameters in lipidThe common formulation of propofol is an oil-in-water (o/w)
lipid emulsion, which contains an equal amount of medium-
chain triglycerides (MCTs) and long-chain triglyceridesharmaceutical Chemistry
Wei).
ministration, Taiwan. Publemulsion preparation are particle size and particle size dis-
tribution [1,2]. Intravenous administration of fat droplets with
diameters larger than 5 mmhas been reported to be associated
with severe adverse effects, such as emboli in the lungs [3]., College of Pharmacy, China Medical University, Taichung 404,
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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specific globule size distribution limits in Chapter 729 [4].
According to USP, the mean droplet diameter (MDD) should
not exceed 500 nm, and the large-diameter tail, expressed as
the volume-weighted percent of fat droplets exceeding 5 mm
(PFAT5), should not exceed 0.05% of the total lipid
concentration.
Several studies have shown that lipid injectable emulsions
stored in plastic containers exceed the PFAT5 limits proposed
by USP <729>, making plastic container less suitable than
glass containers [5,6]. Recently, a study showed oxidative
stress and tissue damage in the lung and liver of rats following
a 24-hour infusion of an unstable lipid emulsion admixture
(PFAT5 > 0.05%) [7]. In clinical practice, well-documented in-
formation about the stability of an opened drug formulation
after dilution in various vehicles is critical. However, very few
studies have addressed this issue. In the present study, we
mimicked the clinical environment to investigate the physical
stability of propofol emulsions. Specifically, our previous
study found that 2.0 mg/mL and 2.5 mg/mL propofol MCT/LCT
emulsions went opalescent and developed small oil droplets
when prepared in a 0.9% NaCl medium followed by packaged
in a nonpolyvinyl chloride (non-PVC; Cryovac polyolefins)
soft bag container, and then stored at an ambient temperature
without protection from light for 8 days [8]. The purpose of
this study was to evaluate the effects of glass and plastic
containers on the physicochemical properties of a mixture of
propofol MCT/LCT in a 0.9% NaCl medium using the proposed
methods and the globule size distribution limits given in USP
Chapter 729. In the case of plastic containers, although PVC is
a widely used material that can meet the rigorous re-
quirements for medical products consistently, it may not be
appropriate for all clinical applications. PVC is considered
environmentally unsafe because it contributes to dioxin for-
mation during manufacture and incineration. As to the
chemical di-(2-ethylhexyl)-phthalate, the most widely used
plasticizer in PVC medical devices, has demonstrated poten-
tial problems such as liver damage and testicular atrophy,
especially in neonates and infants under 1 year of age [9].
Therefore, it has become a worldwide trend to change from
PVC to non-PVC plastic containers. We analyzed both particle
size and particle size distribution of propofol MCT/LCT inTable 1 e Composition of propofol formulations and initial ph
Component
2.0 2.5
10 mg/mL propofol (mL) 200 250
0.9% NaCl (mL) 800 750
Total volume (mL) 1000 1000
Final propofol concentration (mg/mL) 2.0 2.5
Final NaCl concentration (%) 0.72 0.675
Final lipid concentration (mg/mL) 20 25
pH 6.39  0.02 6.45  0.0
Osmolarity (mOsm/kg) 292.0  0.0 293.8  1
MDD (nm) 292.5  5.0 297.5  1
PFAT5 (%) 0.0031  0.0015 0.0021 
MDD ¼ mean droplet diameter; PFAT5 ¼ volume-weighted percent of fat0.9% NaCl and compared them with glass and two types of
plastic containers, including the non-PVC Cryovac polyolefin
soft bag containers and PVC containers.2. Methods
2.1. Study drug
Propofol MCT/LCT were supplied by Chi Sheng Chemical
Corporation (Hsinchu, Taiwan) as an injectable emulsion in a
50 mL glass vial (10 mg/mL). Propofol is formulated as a lipid
emulsion with 10% MCT/LCT and contains approximately
100 mg fat per milliliter. Propofol also contains glycerin
(22.5 mg/mL) and purified egg yolk phospholipids (12 mg/mL),
and has a pH of 6.0e8.5.
2.2. Solvent for dilution and containers
The 0.9% NaCl solution (Chi Sheng Chemical Corporation)
used to dilute the propofol MCT/LCTwas supplied in Cryovac
polyolefin soft bag containers (Sealed Air, NJ, USA), PVC soft
bag containers (Bioteque Corporation, Ilan, Taiwan), and glass
bottles (Chi Sheng Chemical Corporation).
2.3. Study design
Five concentrations of propofol MCT/LCT (2.0 mg/mL,
2.5 mg/mL, 3.0 mg/mL, 4.0 mg/mL, and 5.0 mg/mL) were pre-
pared (Table 1) according to published recommendations [10].
The solutions of propofol MCT/LCT in glass, Cryovac
polyolefin, or PVC soft bag containers (100 mL) were stored at
25 2C/50 5% RH in a room controlled by an air conditioner
during the experimental period. These conditions resemble
those any diluted drug solution is liable to encounter in clin-
ical practice prior to being administrated to a patient. Samples
in glass, Cryovac polyolefins, and PVC soft bags were in
triplicate. The supplier recommends that diluted emulsion of
propofol MCT/LCT should not be frozen because the emulsion
is liable to break down at low temperatures.
For each preparation, the first sample was taken immedi-
ately after dilution and bottling (sampling time T0), whichysicochemical properties.
Propofol concentration (mg/mL)
3.0 4.0 5.0
300 400 500
700 600 500
1000 1000 1000
3.0 4.0 5.0
0.63 0.54 0.45
30 40 50
4 6.49  0.03 6.55  0.04 6.60  0.04
.5 294.8  0.5 299.8  0.5 304.3  0.5
7.1 315.0  12.9 310.0  16.3 305.0  5.8
0.0003 0.0029  0.0002 0.0032  0.0002 0.0033  0.0001
droplets exceeding 5 mm.
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6 hours, 24 hours, 48 hours, and 72 hours of storage.2.4. Analytical methods
For the qualitative determination of MDD, a totally scattering
measurement instrument (Institute of Particle and Two-Phase
Flow Measurement University of Shanghai for Science and
Technology, Shanghai, China) was used (range, 50e5000 nm)
[11]. After the sample container was inverted 20 times, sample
aliquots were analyzed using filtered distilled water as a
diluent with a sample relative index of 1.095, which was the
ratio of refractive index of MCT/LCT oil droplets to distilled
water. This sample mixture was swirled gently and injected.
Emulsion samples passed the limits of USP <729> if the
average intensity-weighted MDD result was < 500 nm.
The large-diameter tail assessments were performed on a
liquid particle counter, consisting of an APSS-200 counter
connected to a LiQuilaz-E20 sensor equippedwith a laser diode
(12 mW, 780 nm), an automatic bottle sampler, and an LS-200
(Particle Measuring System Inc., Boulder, CO, USA), which
measuredparticle distribution between2.0 mmand125 mmbya
light-obscurationparticle-countingmethod. Inorder to remain
sufficiently below the nominal coincidence limit for this in-
strument (i.e., w10,000 globules/mL, cumulative), dilution
factors ranged from100 to 30,000 to achieve anacceptable level
of cumulative particle counts within the targeted range of
1000e8000 counts/mL. Samples were analyzed in triplicate.
Calculation and technique for employing a particle counter to
assess the number of large oil droplets present in a lipid
emulsion have been described elsewhere [12,13]. The particleTable 2 e Summary of physicochemical measurements of prop
different time intervals.
Concentration
(mg/mL)
Time (h) pH (mean  SD
Glass Non-PVC
2.0 6 6.40  0.04 6.43  0.02
24 6.29  0.07 6.37  0.02
48 6.31  0.02 6.34  0.04
72 6.33  0.05 6.34  0.02
2.5 6 6.45  0.03 6.45  0.01
24 6.36  0.04 6.32  0.03
48 6.36  0.03 6.31  0.02
72 6.42  0.03 6.33  0.02
3.0 6 6.51  0.02 6.48  0.03
24 6.38  0.01 6.37  0.03
48 6.39  0.02 6.38  0.05
72 6.43  0.02 6.42  0.03
4.0 6 6.54  0.04 6.55  0.04
24 6.47  0.03 6.45  0.04
48 6.45  0.05 6.42  0.03
72 6.50  0.03 6.49  0.03
5.0 6 6.61  0.04 6.59  0.04
24 6.52  0.03 6.51  0.04
48 6.52  0.03 6.51  0.04
72 6.55  0.05 6.54  0.02
PVC ¼ polyvinyl chloride; SD ¼ standard deviation.
a Each formulationwas studied in triplicate per type of container (i.e., glassize data are normalized to the percentage of fat in the lipid
emulsion that is present as particle above a specified diameter
by conversion to a volume basis. Normalization of the data
requires conversion of results for each size channel to its
equivalent spherical volume (ESV)using the following formula:
ESV

cm3
 ¼ ðp D3Þ
6
[1]
where D is the diameter in centimeters of each size channel
and ESV is expressed in cubic centimeters. Next, the number
of particles counted in the bin of that particular size is
multiplied by the ESV for that size bin, yielding a calculated
total spherical volume (TSV) for a given channel of data:
TSV ¼ number of particles  ESV [2]
The percentage of fat concentration of the propofol for-
mulations existing as enlarged lipid globules is then calcu-
lated using the following formula:
% Fat
¼

100 ½TSV ðcm
3Þ  density ðg=mLÞ  dilution factor
½ sample volume ðcm3Þ  fat composition ðg=mLÞ

[3]
where the density of MCT/LCT was set equal to 0.93 g/mL.
PFAT5 value was the calculated data for the globule size dis-
tribution greater than 5 mm. The sample passed the limits of
USP <729> if the volume-weighted percentage of fat residing
in globules >5 mm or PFAT5 value was <0.05%.
Fat globule counts, from triple samples, were taken at time
0 hours, and then at 6 hours, 24 hours, 48 hours, and 72 hours
after mixing. In addition, detail visual analyses wereofol emulsiona stored in three types of containers at
) Osmolarity (mean  SD)
PVC Glass Non-PVC PVC
6.49  0.04 290.3  1.0 291.5  1.7 292.0  1.8
6.38  0.04 293.3  3.5 291.8  2.2 293.0  1.4
6.33  0.03 293.5  2.4 294.0  2.4 294.8  1.7
6.36  0.02 294.3  1.7 294.8  1.0 295.5  1.7
6.50  0.03 292.8  1.0 294.3  2.2 295.0  2.4
6.37  0.01 293.8  3.8 295.8  2.2 295.3  1.5
6.33  0.04 294.0  4.1 297.3  2.9 297.5  2.5
6.35  0.04 294.0  3.2 298.3  2.9 299.3  1.0
6.45  0.02 294.8  1.5 296.3  2.9 296.0  1.4
6.36  0.04 294.0  3.7 296.5  3.5 297.5  1.0
6.37  0.05 297.3  3.3 298.8  3.4 299.0  0.8
6.39  0.01 297.8  3.6 302.5  4.2 303.3  3.9
6.51  0.03 299.5  3.8 300.0  4.2 300.3  1.5
6.43  0.03 302.3  2.5 302.5  1.3 304.0  2.4
6.39  0.02 301.8  3.3 303.0  4.3 304.0  0.8
6.47  0.04 302.3  3.8 305.8  3.8 306.5  3.9
6.58  0.04 302.8  3.0 304.8  4.7 305.0  1.4
6.49  0.03 302.8  1.0 305.0  2.9 307.0  3.6
6.47  0.03 304.8  2.2 306.8  2.6 307.8  1.5
6.51  0.02 305.5  3.5 308.3  2.2 309.5  2.4
s, non-PVC Cryovac polyolefin soft bag, and PVC soft bag containers).
Table 3 e Summary of globule size distribution of propofol emulsion stored in three types of containers at different time
intervals.
Concentration
(mg/mL)
Time (h) PFAT5 (%) (mean  SD) Mean size (nm) (mean  SD)
Glass Non-PVC PVC Glass Non-PVC PVC
2.0 6 0.017  0.003 0.017  0.012 0.009  0.005 330  12 328  21 313  32
24 0.011  0.003 0.017  0.005 0.013  0.005 318  13 333  10 323  26
48 0.030  0.018 0.008  0.005 0.010  0.004 323  5 348  26 340  38
72 0.029  0.003 0.006  0.001 0.011  0.005 343  21 333  5 323  22
2.5 6 0.013  0.008 0.010  0.003 0.005  0.003 305  6 310  8 305  17
24 0.012  0.005 0.016  0.005 0.019  0.008 310  8 328  15 340  62
48 0.023  0.013 0.014  0.005 0.020  0.011 313  10 350  8 368  10
72 0.025  0.011 0.034  0.030 0.022  0.009 365  10 388  52 335  25
3.0 6 0.011  0.004 0.010  0.002 0.004  0.002 318  21 308  10 298  10
24 0.021  0.011 0.013  0.004 0.080  0.009a 310  8 323  21 360  48
48 0.021  0.011 0.150  0.016a 0.247  0.129a 315  13 363  21 345  17
72 0.024  0.010 0.201  0.080a 0.441  0.171a 343  5 348  17 353  13
4.0 6 0.011  0.009 0.004  0.002 0.004  0.002 320  8 310  8 308  10
24 0.028  0.007 0.094  0.026a 0.222  0.043a,c,d 315  6 315  27 343  22
48 0.021  0.003 0.239  0.031a 0.229  0.122a 335  6 385  33 353  19
72 0.020  0.010 4.744  3.130a,c 1.332  0.758a,d 375  6 433  5g 370  8
5.0 6 0.006  0.001 0.002  0.001 0.002  0.001 313  5 300  8 308  17
24 0.015  0.006 0.118  0.056a,c 0.224  0.041a,c,d 320  14 315  17 350  8
48 0.024  0.006 0.876  0.267a,c 0.492  0.178a,c,d 343  13 450  16e 350  22f
72 0.017  0.006 4.049  1.217a,c 1.443  0.798a,d 335  10 1585  631b,e 453  128f
MDD ¼ mean droplet diameter; PFAT5 ¼ volume-weight percent of fat droplets exceeding 5 mm; PVC ¼ polyvinyl chloride; SD ¼ standard de-
viation.
aIt does not meet criteria of PFAT5 < 0.05%.
bIt does not meet criteria of MDD < 500 nm.
cp < 0.001 for PFAT5 comparison with glass container.
dp < 0.001 for PFAT5 comparison with non-PVC container.
ep < 0.001 for MDD comparison with glass container.
fp < 0.001 for MDD comparison with non-PVC container.
gp < 0.001 for MDD comparison with 5.0 mg/mL non-PVC container at 72 h.
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creaming and phase separation with the liberation of free oil.
The pH was measured using microcomputer pH/mV/Ion/
Temp meter of model 6219 (JENCO Electronics, Ltd, Shanghai,
China). The osmolarity was assayed using an Osmometer
Modal 3250 (Advanced Instruments Inc., Norwood, MA, USA).
2.5. Statistical analysis
The results are presented as mean  standard deviation (SD)
values. All measurements were made in triplicate. The data
were analyzed using GraphPad Prism 5.0 (GraphPad Software,
San Diego, CA, USA). For multiple comparisons, we used a
one-way ANOVA, followed by the NewmaneKeuls multiple
comparison test. The priori level of significance was 0.001.3. Results and discussion
Significant parameters related with stability, including pH,
osmolarity, percentage of fat residing in globules which are
greater than 5 mm in size (PFAT5), and MDD, were examined
in the present study. Compositions of different propofol
formulations are presented in Table 1. For each formulation,
the sample was collected immediately after dilution andbottling to determine the baseline values. According to our
analysis, the baseline pH values ranged from 6.39 to 6.60,
whereas osmolarity ranged from 292.0 mOsm/kg to
304.3 mOsm/kg. Initial reported PFAT5 values ranged from
0.0021% to 0.0033%, whereas the MDD ranged from 292.5 nm
and 315.0 nm. No significant difference was observed in
MDD and PFAT5 values among five different propofol
formulations.
Physicochemical assessments of pH and osmolarity for
propofol emulsions stored in three different types of con-
tainers at each time interval are summarized in Table 2. We
found that the pH of propofol emulsion in glass and plastic
containers decreased slightly. This time-dependent pH
decrease in emulsion is independent of container type and
may be a result of the production of free fatty acids after
phospholipid hydrolysis in an aqueous system [14]. We also
found that the osmolarity in plastic containers increased
slightly after 72 hours. PVC and Cryovac non-PVC bags,
compared to glass containers, may accelerate permeability of
water vapor. Overall, the pH and osmolarity of admixture
were consistent among different propofol emulsion formula-
tions. All samples did not show yellow oil droplets and
remained as a uniform phase at the end of the study.
The globule size distribution of propofol emulsion is
summarized in Table 3. In the glass container group, both
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0.0021e0.0033%; at 72 hours: 0.017e0.029%; MDD, at 0 hour:
292.5e315 nm; at 72 hours: 335e375 nm), but all values were
below the USP <729> limits. However, in the non-PVC Cry-
ovac polyolefin soft bag container group, for propofol with
concentrations of 3.0 mg/mL, 4.0 mg/mL, and 5.0 mg/mL, the
reported PFAT5 values at the end of study (72 hours) were
0.201  0.08%, 4.744  3.130%, and 4.049  1.217%, respec-
tively. All exceed the 0.05% limit suggested by USP. Addi-
tionally, the reported MDD values increased over time for
propofol with concentrations of 4.0 mg/mL and 5.0 mg/mL.
The MDD value even exceeded the 500 nm limit suggested by
USP for propofol with concentration of 5.0 mg/mL at 72
hours. Similarly, propofol with concentrations of 3.0 mg/mL,
4.0 mg/mL, and 5.0 mg/mL became unstable when stored in a
PVC soft bag; at 72 hours, all the PFAT5 values exceeded the
USP limit and the relevant MDD values were very close to the
500 nm limit.
Differences of the large-diameter fat globule populations
in the glass and plastic container groups were observed.
Instability of the emulsions in plastic bags was observed as
early as 24 hours. A trend of distribution of large-diameter
globules was observed among different propofol formula-
tions. Specifically, in the case of plastic containers, the
highest PFAT5 value was detected in propofol with the
highest concentration (5.0 mg/mL). Importantly, after 5 days,
sample solutions (4.0 mg/mL and 5.0 mg/mL) stored in non-
PVC and PVC soft bag containers became opalescent and
developed small oil droplets. These findings strongly sug-
gested that plastic containers affect the physical stability of
propofol emulsion.
The physical stability of lipid injectable emulsions is
influenced primarily by the native lipid emulsion and the final
concentration of electrolytes. Instability appears when the
stabilizing negative charge on the surface of the oil droplets is
neutralized by oppositely charged ions (e.g., sodium) [15].
Neutralization of droplet charges by electrolytes allows the
attractive Van der Waals force to predominate and hence the
emulsion flocculates. Other factors, such as mass transport,
may also participate and influence the physical stability [16].
Emulsions are unstable exhibiting flocculation, coalescence,
creaming, and degradation by diffusion. Mass transport
among droplets is typically driven by differences in size and
composition because they impose differences in chemical
potential of the solutes in each environment.
In conclusion, comparing propofol formulations of higher
concentrations (4.0mg/mL and 5.0mg/mL) with those of lower
concentrations (2.0 mg/mL and 2.5 mg/mL), we found that the
formulations at higher concentrations have more proportion
of lipid, indicating more lipid and ion interactions at the sur-
face area. Such interactions may enhance the aggregation,
fusion, or coalescence of submicron droplets, ultimately
leading to the formation of large-diameter fat globules (i.e.,
5 mm). We therefore recommend that the propofol emulsion
should be packaged into glass containers for storage and de-
livery. The propofol emulsion reconstituted with diluents for
injection should be prepared immediately prior to adminis-
tration and must be used within 6 hours.Acknowledgments
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